Unlike that for infliximab and adalimumab, which are widely used in IBD patients, no data on the risk associated with therapy with other anti-TNF agents, such as golimumab and certolizumab pegol, in IBD patients complicated with lymphomas have been available. Here, TNF is linked to lymphoma.